Microbix Biosystems (TSE:MBX) Director Purchases C$32,200.00 in Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino purchased 115,000 shares of Microbix Biosystems stock in a transaction that occurred on Thursday, May 28th. The shares were acquired at an average price of C$0.28 per share, with a total value of C$32,200.00. Following the acquisition, the director directly owned 2,000,167 shares of the company’s stock, valued at C$560,046.76. This trade represents a 6.10% increase in their position.

Martin Marino also recently made the following trade(s):

• On Tuesday, May 26th, Martin Marino purchased 69,000 shares of Microbix Biosystems stock. The shares were acquired at an average price of C$0.26 per share, with a total value of C$17,940.00.
• On Wednesday, May 27th, Martin Marino purchased 24,500 shares of Microbix Biosystems stock. The shares were acquired at an average price of C$0.26 per share, with a total value of C$6,370.00.

Microbix Biosystems Stock Performance

Microbix Biosystems stock traded down C$0.01 during midday trading on Thursday, reaching C$0.28. 190,765 shares of the company’s stock were exchanged, compared to its average volume of 62,796. Microbix Biosystems Inc. has a 52 week low of C$0.21 and a 52 week high of C$0.34. The company has a debt-to-equity ratio of 27.03, a quick ratio of 5.57 and a current ratio of 5.35. The firm has a market cap of C$37.81 million, a price-to-earnings ratio of -6.71 and a beta of 0.48. The stock’s 50-day simple moving average is C$0.24 and its 200 day simple moving average is C$0.24.

Microbix Biosystems (TSE:MBX) last posted its quarterly earnings results on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. The business had revenue of C$3.38 million for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%. On average, analysts expect that Microbix Biosystems Inc. will post 0.02 earnings per share for the current fiscal year.

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.